Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats

Addiction Biology

Volumn 13, Issue 1, 2008, Pages 15-25

  Kobeissy, Firas H ^a   Jeung, Jennifer A ^a   Warren, Matthew W ^a   Geier, Jacqueline E ^a   Gold, Mark S ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Ghrelin; Growth hormone; Leptin; MDMA; Methamphetamine; Neuropeptide Y

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; GHRELIN; GROWTH HORMONE; LEPTIN; METHAMPHETAMINE; NEUROPEPTIDE Y;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABUSE; DRUG EXPOSURE; FOOD INTAKE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE-RELATED DISORDERS; ANIMALS; APPETITE; BODY WEIGHT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GHRELIN; GROWTH HORMONE; LEPTIN; MALE; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPEPTIDE Y; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38849209310     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2007.00083.x     Document Type: Article

References (53)

1. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911 916.
2. Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24: 3436 3443.
3. Baumann MH, Wang X, Rothman RB (2007) 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189: 407 424.
4. Chan YY, Steiner RA, Clifton DK (1996) Regulation of hypothalamic neuropeptide-Y neurons by growth hormone in the rat. Endocrinology 137: 1319 1325.
5. Cho AK, Melega WP, Kuczenski R, Segal DS (2001) Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39: 161 166.
6. Crane C, Akhter N, Johnson BW, Iruthayanathan M, Syed F, Kudo A, Zhou YH, Childs GV (2007) Fasting and glucose effects on pituitary leptin expression: is leptin a local signal for nutrient status? J Histochem Cytochem Epub ahead of print (2007 June 26; PMID: 17595338).
7. Crowley WR, Ramoz G, Keefe KA, Torto R, Kalra SP, Hanson GR (2005) Differential effects of methamphetamine on expression of neuropeptide Y mRNA in hypothalamus and on serum leptin and ghrelin concentrations in ad libitum-fed and schedule-fed rats. Neuroscience 132: 167 173.
8. Curzon G, Gibson EL, Oluyomi AO (1997) Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 18: 21 25.
9. Daberkow DP, Kesner RP, Keefe KA (2005) Relation between methamphetamine-induced monoamine depletions in the striatum and sequential motor learning. Pharmacol Biochem Behav 81: 198 204.
10. Dafters RI (1995) Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 58: 877 882.
11. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36: 1 22.
12. Davidson C, Lee TH, Ellinwood EH (2005) Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int 46: 189 203.
13. De Souza I, Kelly JP, Harkin AJ, Leonard BE (1997) An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol Toxicol 80: 207 210.
14. Deng X, Ladenheim B, Tsao LI, Cadet JL (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J Neurosci 19: 10107 10115.
15. Dube MG, Sahu A, Phelps CP, Kalra PS, Kalra SP (1992) Effect of d-fenfluramine on neuropeptide Y concentration and release in the paraventricular nucleus of food-deprived rats. Brain Res Bull 29: 865 869.
16. Egecioglu E, Bjursell M, Ljungberg A, Dickson SL, Kopchick JJ, Bergstrom G, Svensson L, Oscarsson J, Tornell J, Bohlooly YM (2006) Growth hormone receptor deficiency results in blunted ghrelin feeding response, obesity, and hypolipidemia in mice. Am J Physiol Endocrinol Metab 290: E317 E325.
17. Faria R, Magalhaes A, Monteiro PR, Gomes-Da-Silva J, Amelia Tavares M, Summavielle T (2006) MDMA in adolescent male rats: decreased serotonin in the amygdala and behavioral effects in the elevated plus-maze test. Ann N Y Acad Sci 1074: 643 649.
18. Federici M, Sebastianelli L, Natoli S, Bernardi G, Mercuri NB (2007) Electrophysiologic changes in ventral midbrain dopaminergic neurons resulting from (+/-)-3,4-methylenedioxymethamphetamine (MDMA-'ecstasy'). Biol Psychiatry 62: 680 686.
19. Gayle DA, Desai M, Casillas E, Beloosesky R, Ross MG (2006) Gender-specific orexigenic and anorexigenic mechanisms in rats. Life Sci 79: 1531 1536.
20. Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R, Laviola G, Macchia T, Brambilla F (2002) Effects of (+/-)3,4-methylene- dioxymethamphetamine (ecstasy) on dopamine system function in humans. Behav Brain Res 134: 403 410.
21. Ginawi OT, Al-Majed AA, Al-Suwailem AK (2005a) NAN-190, a possible specific antagonist for methamphetamine. Regul Toxicol Pharmacol 41: 122 127.
22. Ginawi OT, Al-Majed AA, Al-Suwailem AK (2005b) Ondansetron, a selective 5-HT3 antagonist, antagonizes methamphetamine-induced anorexia in mice. Pharmacol Res 51: 255 259.
23. Guy J, Pelletier G (1988) Neuronal interactions between neuropeptide Y (NPY) and catecholaminergic systems in the rat arcuate nucleus as shown by dual immunocytochemistry. Peptides 9: 567 570.
24. Halford JC, Blundell JE (2000) Pharmacology of appetite suppression. Prog Drug Res 54: 25 58.
25. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539 553.
26. Hernandez L, Hoebel BG (1988) Feeding and hypothalamic stimulation increase dopamine turnover in the accumbens. Physiol Behav 44: 599 606.
27. Hosoda H, Kojima M, Kangawa K (2002) Ghrelin and the regulation of food intake and energy balance. Mol Interv 2: 494 503.
28. Hsieh YS, Yang SF, Chiou HL, Kuo DY (2006) Activations of c-fos/c-jun signaling are involved in the modulation of hypothalamic superoxide dismutase (SOD) and neuropeptide Y (NPY) gene expression in amphetamine-mediated appetite suppression. Toxicol Appl Pharmacol 212: 99 109.
29. Jaehne EJ, Salem A, Irvine RJ (2005) Effects of 3,4- methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation. Pharmacol Biochem Behav 81: 485 496.
30. Jonas JM, Gold MS (1986) Cocaine abuse and eating disorders. Lancet 1: 390 391.
31. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20: 68 100.
32. Kalra SP, Kalra PS (2004) Overlapping and interactive pathways regulating appetite and craving. J Addict Dis 23: 5 21.
33. Kleiner KD, Gold MS, Frost-Pineda K, Lenz-Brunsman B, Perri MG, Jacobs WS (2004) Body mass index and alcohol use. J Addict Dis 23: 105 118.
34. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 64: 29 34.
35. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136 145.
36. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001) Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('ecstasy'). Eur J Pharmacol 433: 91 99.
37. Nazrul Islam SK, Jahangir Hossain K, Ahmed A, Ahsan M (2002) Nutritional status of drug addicts undergoing detoxification: prevalence of malnutrition and influence of illicit drugs and lifestyle. Br J Nutr 88: 507 513.
38. Nogueiras R, Tovar S, Mitchell SE, Rayner DV, Archer ZA, Dieguez C, Williams LM (2004) Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. Diabetes 53: 2552 2558.
39. Paul SM, Hulihan-Giblin B, Skolnick P (1982) (+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency for phenylethylamines. Science 218: 487 490.
40. Pelletier G, Simard J (1991) Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. Neurosci Lett 127: 96 98.
41. Salisbury JJ, Wolgin DL (1985) Role of anorexia and behavioral activation in amphetamine-induced suppression of feeding: implications for understanding tolerance. Behav Neurosci 99: 1153 1161.
42. Samanin R, Garattini S (1993) Neurochemical mechanism of action of anorectic drugs. Pharmacol Toxicol 73: 63 68.
43. Sanchez J, Oliver P, Pico C, Palou A (2004) Diurnal rhythms of leptin and ghrelin in the systemic circulation and in the gastric mucosa are related to food intake in rats. Pflugers Arch 448: 500 506.
44. Santolaria F, Perez-Cejas A, Aleman MR, Gonzalez-Reimers E, Milena A, de la Vega MJ, Martinez-Riera A, Gomez-Rodriguez MA (2003) Low serum leptin levels and malnutrition in chronic alcohol misusers hospitalized by somatic complications. Alcohol Alcohol 38: 60 66.
45. Staszewski RD, Yamamoto BK (2006) Methamphetamine-induced spectrin proteolysis in the rat striatum. J Neurochem 96: 1267 1276.
46. Stephenson CP, Hunt GE, Topple AN, McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine 'Ecstasy'-induced c-fos expression in rat brain. Neuroscience 92: 1011 1023.
47. Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W, Goldberg SR, Palmiter RD, Cadet JL (2005) Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci 25: 5273 5279.
48. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357: 354 357.
49. Wang X, Baumann MH, Xu H, Morales M, Rothman RB (2005) (+/-)-3,4-Methylenedioxymethamphetamine administration to rats does not decrease levels of the serotonin transporter protein or alter its distribution between endosomes and the plasma membrane. J Pharmacol Exp Ther 314: 1002 1012.
50. Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK (2005) Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: a similar profile to traumatic brain injury. Life Sci 78: 301 309.
51. Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK (2006) Ecstasy toxicity: a comparison to methamphetamine and traumatic brain injury. J Addict Dis 25: 115 123.
52. Warren MW, Zheng W, Kobeissy FH, Cheng Liu M, Hayes RL, Gold MS, Larner SF, Wang KK (2007) Calpain- and caspase-mediated alphaII-spectrin and tau proteolysis in rat cerebrocortical neuronal cultures after ecstasy or methamphetamine exposure. Int J Neuropsychopharmacol 10: 479 489.
53. Yu J, Wang J, Cadet JL, Angulo JA (2004) Histological evidence supporting a role for the striatal neurokinin-1 receptor in methamphetamine-induced neurotoxicity in the mouse brain. Brain Res 1007: 124 131.